Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Francesco Mincione, Alessio Nocentini & Claudiu T. Supuran. (2021) Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opinion on Drug Discovery 16:10, pages 1209-1225.
Read now
Read now
Wesam Shamseldin Shalaby, Vikram Shankar, Reza Razeghinejad & L. Jay Katz. (2020) Current and new pharmacotherapeutic approaches for glaucoma. Expert Opinion on Pharmacotherapy 21:16, pages 2027-2040.
Read now
Read now
Emanuela Berrino & Claudiu T Supuran. (2019) Rho-kinase inhibitors in the management of glaucoma. Expert Opinion on Therapeutic Patents 29:10, pages 817-827.
Read now
Read now
Emily M. Schehlein, Gary Novack & Alan L. Robin. (2017) New pharmacotherapy for the treatment of glaucoma. Expert Opinion on Pharmacotherapy 18:18, pages 1939-1946.
Read now
Read now
Toshihiro Inoue & Hidenobu Tanihara. (2017) Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. Expert Opinion on Pharmacotherapy 18:15, pages 1669-1673.
Read now
Read now
Mark S. Dikopf, Thasarat S. Vajaranant & Deepak P. Edward. (2017) Topical treatment of glaucoma: established and emerging pharmacology. Expert Opinion on Pharmacotherapy 18:9, pages 885-898.
Read now
Read now
Tomoyuki Isobe, Masayuki Ohta, Yoshio Kaneko & Hiroyuki Kawai. (2016) Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase. Xenobiotica 46:7, pages 579-590.
Read now
Read now
Articles from other publishers (62)
Akira Takahara, Manami Matsumoto, Akira Sato, Shuto Inose, Megumi Aimoto & Yoshinobu Nagasawa. (2023) Role of Rho Kinase in Regulating Arterial Stiffness in Anesthetized Rabbits. Biological and Pharmaceutical Bulletin 46:12, pages 1846-1850.
Crossref
Crossref
Inès Aouimeur, Tomy Sagnial, Louise Coulomb, Corantin Maurin, Justin Thomas, Pierre Forestier, Sandrine Ninotta, Chantal Perrache, Fabien Forest, Philippe Gain, Gilles Thuret & Zhiguo He. (2023) Investigating the Role of TGF-β Signaling Pathways in Human Corneal Endothelial Cell Primary Culture. Cells 12:12, pages 1624.
Crossref
Crossref
Mingsong Shi, Jiang Liu, Suhong Fu, Heying Pei, Bin Peng, Yi Wen, Haoche Wei, Xin Zhou, Lijuan Chen & Dingguo Xu. (2023) Structural Insights into the Interactions of Belumosudil with Rho-Associated Coiled-Coil Containing Protein Kinases 1 and 2 Based on Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculations. Journal of Computational Biophysics and Chemistry 22:04, pages 401-422.
Crossref
Crossref
Roshan Karri & Elaine W. Chong. (2023)
ROCK
inhibitors in ophthalmology: A critical review of the existing clinical evidence
. Clinical & Experimental Ophthalmology.
Crossref
Crossref
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Koji Kawakita, Satoshi Kojima, Mizuho Kanazawa, Toshiaki Nojima & Hideki Suganami. (2023) Ripasudil–Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials. American Journal of Ophthalmology 248, pages 35-44.
Crossref
Crossref
Pere Català, Gilles Thuret, Heli Skottman, Jodhbir S. Mehta, Mohit Parekh, Sorcha Ní Dhubhghaill, Rob W. J. Collin, Rudy M. M. A. Nuijts, Stefano Ferrari, Vanessa L. S. LaPointe & Mor M. Dickman. (2023) Medizinische Ansätze zur Regeneration des Hornhautendothels. Kompass Ophthalmologie 9:3, pages 83-101.
Crossref
Crossref
Lloyd R. Kopecny, Brendon W.H. Lee & Minas T. Coroneo. (2023) A systematic review on the effects of ROCK inhibitors on proliferation and/or differentiation in human somatic stem cells: A hypothesis that ROCK inhibitors support corneal endothelial healing via acting on the limbal stem cell niche. The Ocular Surface 27, pages 16-29.
Crossref
Crossref
Marie Suzuki, Yohei Suzuki, Ryohei Komori, Yusuke Orii, Shogo Arimura, Kentaro Iwasaki, Yoshihiro Takamura & Masaru Inatani. (2022) Aqueous column changes in the episcleral veins after the instillation of ripasudil versus latanoprost: a randomized, double-blind, crossover clinical trial. Scientific Reports 12:1.
Crossref
Crossref
Josefine Clement Freiberg, Alexander von Spreckelsen, Miriam Kolko, Augusto Azuara-Blanco & Gianni Virgili. (2022) Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension. Cochrane Database of Systematic Reviews 2022:6.
Crossref
Crossref
Pere Català, Gilles Thuret, Heli Skottman, Jodhbir S. Mehta, Mohit Parekh, Sorcha Ní Dhubhghaill, Rob W.J. Collin, Rudy M.M.A. Nuijts, Stefano Ferrari, Vanessa L.S. LaPointe & Mor M. Dickman. (2022) Approaches for corneal endothelium regenerative medicine. Progress in Retinal and Eye Research 87, pages 100987.
Crossref
Crossref
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente-Macías, Daniel J. Baillache, Stephen Croke & Asier Unciti-Broceta. (2021) Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry 65:2, pages 1047-1131.
Crossref
Crossref
Sapna Sinha, Wesam Shamseldin Shalaby, Wendy W. Liu, Reza Razeghinejad & L. Jay Katz. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
612
661
.
. 2022. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics
67
89
.
C.H. McAteer, R. Murugan & J.H. Yamamoto. 2022. Comprehensive Heterocyclic Chemistry IV. Comprehensive Heterocyclic Chemistry IV
217
242
.
Masahiro FuwaAtsushi ShimazakiNoriko Odani-KawabataTomoko KiriharaTakazumi TaniguchiRyo IwamuraKenji YonedaMasatomo KatoKenji MorishimaNaveed K. Shams. (2021) Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. Journal of Ocular Pharmacology and Therapeutics 37:4, pages 223-229.
Crossref
Crossref
Hon Shing Ong, Marcus Ang & Jodhbir Mehta. (2021) Evolution of therapies for the corneal endothelium: past, present and future approaches. British Journal of Ophthalmology 105:4, pages 454-467.
Crossref
Crossref
Guorong Li, Chanyoung Lee, A Thomas Read, Ke Wang, Jungmin Ha, Megan Kuhn, Iris Navarro, Jenny Cui, Katherine Young, Rahul Gorijavolu, Todd Sulchek, Casey Kopczynski, Sina Farsiu, John Samples, Pratap Challa, C Ross Ethier & W Daniel Stamer. (2021) Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis. eLife 10.
Crossref
Crossref
Takayuki KamiyaTsuneaki OmaeSeigo NakabayashiKengo TakahashiAkira TannerAkitoshi Yoshida. (2021) Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles. Journal of Ocular Pharmacology and Therapeutics 37:2, pages 104-111.
Crossref
Crossref
Xutong Li, Zhaojun Li, Xiaolong Wu, Zhaoping Xiong, Tianbiao Yang, Zunyun Fu, Xiaohong Liu, Xiaoqin Tan, Feisheng Zhong, Xiaozhe Wan, Dingyan Wang, Xiaoyu Ding, Ruirui Yang, Hui Hou, Chunpu Li, Hong Liu, Kaixian Chen, Hualiang Jiang & Mingyue Zheng. (2019) Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation. Journal of Medicinal Chemistry 63:16, pages 8723-8737.
Crossref
Crossref
Laijun Song, Chunyu Zhu, Wenxin Zheng, Dan Lu, Hong Jiao, Rongbing Zhao & Zhonglei Bao. (2020) Computational systematic selectivity of the Fasalog inhibitors between ROCK-I and ROCK-II kinase isoforms in Alzheimer’s disease. Computational Biology and Chemistry 87, pages 107314.
Crossref
Crossref
Akiko Futakuchi, Takeshi Morimoto, Yoko Ikeda, Hidenobu Tanihara, Toshihiro Inoue, Makoto Aihara, Shogo Arimura, Takeo Fukuchi, Tomomi Higashide, Megumi Honjo, Masaru Inatani, Kenji Inoue, Kyoko Ishida, Makoto Ishikawa, Keiichiro Iwao, Hiroshi Kakimoto, Kazuhide Kawase, Akitoshi Kimura, Shigeru Kinoshita, Yoshiaki Kiuchi, Taiki Kokubun, Shigeto Maekawa, Kazunori Miyata, Kazuhiko Mori, Shunsuke Nakakura, Natsuko Nakamura, Makoto Nakamura, Toru Nakazawa, Kenichi Namba, Takashi Nishida, Nobuyuki Ohguro, Shinichiro Ohtani, Hideaki Okumichi, Mari Sakamoto, Akira Sawada, Minako Shiokawa, Chie Sotozono, Aki Suetake, Kazuhisa Sugiyama, Yuko Takemoto, Kana Tokumo, Goji Tomita, Satsuki Tsuzaki, Sachiko Udagawa, Morio Ueno, Yu Yokoyama, Takeshi Yoshitomi & Yuki Yuasa. (2020) Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study. Scientific Reports 10:1.
Crossref
Crossref
Christopher M. Adams & Julien P. N. Papillon. 2020. Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases. Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases
189
256
.
Emily M. Schehlein & Alan L. Robin. (2019) Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment. Drugs 79:10, pages 1031-1036.
Crossref
Crossref
Hitomi Saito, Shinji Kagami, Koichi Mishima, Naomi Mataki, Atsuki Fukushima & Makoto Araie. (2019) Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil. Journal of Glaucoma 28:4, pages 289-293.
Crossref
Crossref
Toshiyasu Imaizumi, Daijiro Kurosaka, Umi Tanaka, Daisuke Sakai, Kazuhiro Fukuda & Atsushi Sanbe. (2019) Topical administration of a ROCK inhibitor prevents anterior subcapsular cataract induced by UV-B irradiation. Experimental Eye Research 181, pages 145-149.
Crossref
Crossref
Yoshiro Minami, Young-seok Song, Akihiro Ishibazawa, Tsuneaki Omae, Tomoko Ro-mase, Satoshi ishiko & Akitoshi Yoshida. (2019) Effect of ripasudil on diabetic macular edema. Scientific Reports 9:1.
Crossref
Crossref
Cherng-Ru Hsu, Yi-Hsun Chen, Chih-Peng Liu, Chih-Hung Chen, Kuo-Kuei Huang, Jui-Wen Huang, Meng-Nan Lin, Chih-Lung Lin, Wan-Ru Chen, Yi-Ling Hsu, Tze-chung Lee, Shuen-Hsiang Chou, Chia-Mu Tu, Chrong-Shiong Hwang, Yu Chuan Huang & Da-Wen Lu. (2019) A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia. Investigative Opthalmology & Visual Science 60:2, pages 624.
Crossref
Crossref
Yasushi Wada, Tomomi Higashide, Atsushi Nagata & Kazuhisa Sugiyama. (2018) Effects of ripasudil, a rho kinase inhibitor, on blood flow in the optic nerve head of normal rats. Graefe's Archive for Clinical and Experimental Ophthalmology 257:2, pages 303-311.
Crossref
Crossref
Daniel M. Sedgwick, Raquel Román, Pablo Barrio, Andrés A. Trabanco & Santos Fustero. 2019. Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals. Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals
575
606
.
Angelo P. Tanna & Mark Johnson. (2018) Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension. Ophthalmology 125:11, pages 1741-1756.
Crossref
Crossref
Masahiro FuwaCarol B. TorisShan FanTakazumi TaniguchiMasaki IchikawaNoriko Odani-KawabataRyo IwamuraKenji YonedaTakeshi MatsugiNaveed K. ShamsJin-Zhong Zhang. (2018) Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. Journal of Ocular Pharmacology and Therapeutics 34:7, pages 531-537.
Crossref
Crossref
Kenji Inoue, Kyoko Ishida & Goji Tomita. (2018) Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Japanese Journal of Ophthalmology 62:4, pages 508-516.
Crossref
Crossref
Etsuo Chihara, Galina Dimitrova & Tomoyuki Chihara. (2018) Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine. Graefe's Archive for Clinical and Experimental Ophthalmology 256:7, pages 1257-1264.
Crossref
Crossref
Catherine Q. Sun & Yvonne Ou. (2018) New Developments in the Medical Treatment of Glaucoma. Current Ophthalmology Reports 6:2, pages 73-78.
Crossref
Crossref
Hiroshi Inazaki, Satoshi Kobayashi, Yoko Anzai, Hisayoshi Satoh, Shimpei Sato, Maiko Inoue, Shin Yamane & Kazuaki Kadonosono. (2017) One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefe's Archive for Clinical and Experimental Ophthalmology 255:10, pages 2009-2015.
Crossref
Crossref
Yusuke Ohta, Sanae Takaseki & Takeshi Yoshitomi. (2017) Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits. Japanese Journal of Ophthalmology 61:5, pages 423-432.
Crossref
Crossref
Ponugoti Vasantha Rao, Padmanabhan P. Pattabiraman & Casey Kopczynski. (2017) Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research. Experimental Eye Research 158, pages 23-32.
Crossref
Crossref
Vanessa Andrés-Guerrero, Julián García-Feijoo & Anastasios Georgios Konstas. (2017) Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Considerations. Advances in Therapy 34:5, pages 1049-1069.
Crossref
Crossref
Javier CabrerizoJavier A. Urcola & Elena Vecino. (2017) Changes in the Lipidomic Profile of Aqueous Humor in Open-Angle Glaucoma. Journal of Glaucoma 26:4, pages 349-355.
Crossref
Crossref
Hiroshi YamadaMasahiko YonedaShingo InagumaMasahiko GoshoYusuke MurasawaZenzo IsogaiMasahiro Zako. (2017) A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis. Journal of Ocular Pharmacology and Therapeutics 33:3, pages 176-185.
Crossref
Crossref
Emily M. Schehlein, Gary D. Novack & Alan L. Robin. (2017) New classes of glaucoma medications. Current Opinion in Ophthalmology 28:2, pages 161-168.
Crossref
Crossref
Hiroshi Inazaki, Satoshi Kobayashi, Yoko Anzai, Hisayoshi Satoh, Shimpei Sato, Maiko Inoue, Shin Yamane & Kazuaki Kadonosono. (2017) Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy. Journal of Glaucoma 26:2, pages 96-100.
Crossref
Crossref
Muneo Yamaguchi, Shintaro Nakao, Mitsuru Arima, Iori Wada, Yoshihiro Kaizu, Feng Hao, Shigeo Yoshida & Koh-hei Sonoda. (2017) Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases. Journal of Ophthalmology 2017, pages 1-8.
Crossref
Crossref
Yoshio Kaneko, Masayuki Ohta, Tomoyuki Isobe, Yuto Nakamura & Ken Mizuno. (2017) Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys. Journal of Ophthalmology 2017, pages 1-8.
Crossref
Crossref
Tomoyuki IsobeTaku KasaiHiroyuki Kawai. (2016) Ocular Penetration and Pharmacokinetics of Ripasudil Following Topical Administration to Rabbits. Journal of Ocular Pharmacology and Therapeutics 32:7, pages 405-414.
Crossref
Crossref
Shino Sato, Kazuyuki Hirooka, Eri Nitta, Kaori Ukegawa & Akitaka Tsujikawa. (2016) Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy. Advances in Therapy 33:9, pages 1628-1634.
Crossref
Crossref
Lei Wei, Michelle Surma, Stephanie Shi, Nathan Lambert-Cheatham & Jianjian Shi. (2016) Novel Insights into the Roles of Rho Kinase in Cancer. Archivum Immunologiae et Therapiae Experimentalis 64:4, pages 259-278.
Crossref
Crossref
Carol B. TorisMarsha A. McLaughlinDouglas P. DworakShan FanShane HavensGui-Lin ZhanNicholas HoranGanesh Prasanna. (2016) Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits. Journal of Ocular Pharmacology and Therapeutics 32:6, pages 355-364.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2016) Synthetic approaches to the 2014 new drugs. Bioorganic & Medicinal Chemistry 24:9, pages 1937-1980.
Crossref
Crossref
Hidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Yasuaki Kuwayama, Haruki Abe, Atsuki Fukushima, Hideki Suganami & Makoto Araie. (2016) One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmologica 94:1, pages e26-e34.
Crossref
Crossref
Yoshio Kaneko, Masayuki Ohta, Toshihiro Inoue, Ken Mizuno, Tomoyuki Isobe, Sohei Tanabe & Hidenobu Tanihara. (2016) Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Scientific Reports 6:1.
Crossref
Crossref
Anthony F. Alario, Travis D. Strong & Stefano Pizzirani. (2015) Medical Treatment of Primary Canine Glaucoma. Veterinary Clinics of North America: Small Animal Practice 45:6, pages 1235-1259.
Crossref
Crossref
Gervaise Loirand. (2015) Rho Kinases in Health and Disease: From Basic Science to Translational Research. Pharmacological Reviews 67:4, pages 1074-1095.
Crossref
Crossref
Seigo Nakabayashi, Motofumi Kawai, Takafumi Yoshioka, Yong-Seok Song, Tomofumi Tani, Akitoshi Yoshida & Taiji Nagaoka. (2015) Effect of intravitreal Rho kinase inhibitor ripasudil (K-115) on feline retinal microcirculation. Experimental Eye Research 139, pages 132-135.
Crossref
Crossref
Hiroko Nakagawa, Noriko Koizumi, Naoki Okumura, Hideki Suganami & Shigeru Kinoshita. (2015) Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study. PLOS ONE 10:9, pages e0136802.
Crossref
Crossref
Sarah Van de Velde, Lies De Groef, Ingeborg Stalmans, Lieve Moons & Inge Van Hove. (2015) Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Progress in Neurobiology 131, pages 105-119.
Crossref
Crossref
Hidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Yasuaki Kuwayama, Haruki Abe, Hideki Suganami & Makoto Araie. (2014) Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study. Acta Ophthalmologica 93:4.
Crossref
Crossref
Sandro Boland, Arnaud Bourin, Jo Alen, Jacques Geraets, Pieter Schroeders, Karolien Castermans, Nele Kindt, Nicki Boumans, Laura Panitti, Silke Fransen, Jessica Vanormelingen, Jean Marie Stassen, Dirk Leysen & Olivier Defert. (2015) Design, Synthesis, and Biological Evaluation of Novel, Highly Active Soft ROCK Inhibitors. Journal of Medicinal Chemistry 58:10, pages 4309-4324.
Crossref
Crossref
Sarah H. Van Tassel, Nathan M. Radcliffe & Anna M. Demetriades. (2015) One Year of Glaucoma Research in Review—2013 to 2014. Asia-Pacific Journal of Ophthalmology 4:4, pages 228-235.
Crossref
Crossref
Sarah Van de Velde, Tine Van Bergen, Evelien Vandewalle, Nele Kindt, Karolien Castermans, Lieve Moons & Ingeborg Stalmans. 2015. New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System, Part A. New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System, Part A
283
297
.
Karly P. Garnock-Jones. (2014) Ripasudil: First Global Approval. Drugs 74:18, pages 2211-2215.
Crossref
Crossref
Kozo OmichiEiji WatoYoshiki KanekoShigeki YoneyamaAkitaka MatsudaMikio SasakiAdrian Bull, David Coleman, Masataka KagawaYukinori Amano. (2014) Nonclinical safety assessment for the sensitizing potential of K-115. Fundamental Toxicological Sciences 1:1, pages 19-27.
Crossref
Crossref